Century Therapeutics vs Mesoblast
IPSC and MESO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IPSC and MESO compare
Century Therapeutics scores higher on the StockData Score (8 against 6 for Mesoblast), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IPSC | MESO |
|---|---|---|
| Size and price | ||
| Market cap | $315M | – |
| Share price | $1.74 | $13.65 |
| Change, 1 year | 217% | −10.3% |
| Change, 5 years | −91.6% | 9.4% |
| Beta (5Y) | 1.37 | 1.51 |
| Employees | 78 | 108 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.5× | – |
| FCF yield | −27.0% | – |
| Growth | ||
| Revenue growth (TTM) | – | 599% |
| Revenue growth, 5Y average | – | 74.5% |
| Profitability | ||
| Gross margin | – | 86.1% |
| Net margin | – | −47.8% |
| FCF margin | – | −37.1% |
| Return on equity | −51.2% | – |
| Return on invested capital | −126% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 8.74 (better) | 2.43 |
| Altman Z-score | −1.89 | – |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.22% | – |
| Shareholder yield | −0.22% | – |
| Ownership | ||
| Held by institutions | 87.3% | 0.30% |
| Held by insiders | 3.8% | 37.3% |
| Insider net buying, 12 months | $10.6K | $37.5M (better) |
| Short interest, % of float | 18.4% | – |
Go deeper
- IPSC stock overview
- IPSC income statement
- IPSC valuation and score
- MESO stock overview
- MESO income statement
- MESO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.